Janet Gunzner-Toste is the Chief Operating Officer of Exavir Therapeutics. Prior to Exavir, Dr. Gunzner-Toste held roles of increasing responsibility over the past 20 years at Merck, Genentech, Nektar and BridgeBio where she oversaw research and clinical development programs across multiple indications. In her most recent position, VP of Program Management at BridgeBio, Dr. Gunzner-Toste provided development guidance and oversight for the acoramidis program being developed for the treatment of ATTR-CM, currently in Phase 3. Dr. Gunzner-Toste is a co-author on numerous peer-reviewed articles including those in Journal of American Chemical Society and Journal of Medicinal Chemistry, and she is an inventor on multiple patents, including for the marketed medicine Erivedge®. She received her B.A. from Reed College, her Ph.D. from the Scripps Research Institute, her postdoctoral training at Stanford University, and her M.B.A. from the UC Berkeley Walter A. Haas School of Business.